FDA Approves Genentech's Subcutaneous Lunsumio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Source: SeekingAlpha
FDA Approval: The US FDA has approved a subcutaneous version of Roche's Lunsumio (mosunetuzumab) for treating follicular lymphoma, which is quicker to administer than the infusion version.
Treatment Efficacy: Lunsumio VELO received accelerated approval based on a phase I/II study showing a 75% objective response rate and a 59% complete response rate in patients with advanced follicular lymphoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
